Week of May 19 - 25, 2013

Genetic Counseling & Testing for BRCA1 & BRCA2 Gene Mutations
BRCA1 and BRCA2 is short for breast cancer susceptibility gene 1 and breast cancer susceptibility gene 2. The BRCA1 and BRCA2 genes are present in all individuals. Learn more about BRCA1 and BRCA2 now.

Nutrition from A to Z: Answers to Your Nutrition and Diet Questions
Are you confused by all the information on cancer and nutrition; what to eat and what to avoid? The program reviews the current nutritional information and guidelines for cancer patients and survivors. Did you miss our webinar? Listen and watch the archive.

Mistletoe (Viscum album)
This plant’s extract is often used by people with cancer in an effort to boost the immune system and treat side effects of cancer treatment.

After Breast Cancer: Survivor Education Webinar
Watch and listen to the archive of this webinar with Dr. Schmitz, Principal Investigator on the groundbreaking PAL trial, which demonstrated that exercise and weight training, is safe for breast cancer survivors, and decreased the risk of developing lymphedema. Addresses issues that commonly affect breast cancer survivors and explore ways to manage these concerns.

Non-Hodgkin's Lymphoma: Current Strategies, Ongoing Challenges, and Future Treatments in Follicular Lymphoma
New Oncology Medical Minute. Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year.

Introduction to Stereotactic Radiation
Stereotactic radiation, often referred to as stereotactic body radiation therapy (SBRT), stereotactic ablative radiotherapy (SABR) or stereotactic radiosurgery (SRS), is a form of radiation therapy that very precisely delivers a high dose of radiation to a tumor.

An Evidence-Based Approach to Managing Chemotherapy-Induced Nausea and Vomiting - Continuing Education
This continuing education activity is designed for nurses and nurse practitioners in clinical practice to learn about the assessment, prevention and control of chemotherapy-induced nausea and vomiting (CINV). This activity has been approved for 1.0 contact hour.

O-Pro eNews Spring 2013
"O-Pro" is the e-newsletter for oncology professionals. We hope this newsletter will to keep you up to date on what's new and useful for your practice in oncology.

Ado-trastuzumab emtansine (Kadcyla™)
Kadcyla™ is a monoclonal antibody attached to a chemotherapy agent called maytansine (a microtubule inhibitor). Monoclonal antibodies are designed to target a specific type of cell – in this case, a Her2- positive breast cancer cell.

OncoLink's blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.